Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares are trading lower by 19.9% to 72 cents Wednesday afternoon after the company announced a 1-for-8 reverse stock split. What Else: Sonnet ...
Shares of oncology-focused biotechnology company Sonnet BioTherapeutics (SONN) have plummeted more than 70% in price year-to-date due to its poor financials and the broad-based market sell-off.
In a challenging market environment, shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) have reached a 52-week low, dipping to $0.71. This price level reflects significant pressure on the ...
Fintel reports that on April 19, 2023, EF Hutton reiterated coverage of Sonnet BioTherapeutics Holdings (NASDAQ:SONN) with a Buy recommendation. As of April 6, 2023, the average one-year price target ...
Fintel reports that on April 19, 2023, Chardan Capital maintained coverage of Sonnet BioTherapeutics Holdings (NASDAQ:SONN) with a Buy recommendation. As of April 6, 2023, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results